Placebo-controlled double-blind randomized trial on the use of l-carnitine, l- acetylcarnitine, or combined l-carnitine and l-acetylcarnitine in men with idiopathic asthenozoospermia Giancarlo Balercia, M.D., Francesco Regoli, Ph.D., Tatiana Armeni, Ph.D., Aleardo Koverech, M.D., Franco Mantero, M.D., Marco Boscaro, M.D. Fertility and Sterility Volume 84, Issue 3, Pages 662-671 (September 2005) DOI: 10.1016/j.fertnstert.2005.03.064 Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions
FIGURE 1 Forward sperm motility at each time in the four treatment groups: percentage variations with respect to T-1. Balercia. Carnitine therapy in asthenozoospermia. Fertil Steril 2005. Fertility and Sterility 2005 84, 662-671DOI: (10.1016/j.fertnstert.2005.03.064) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions
FIGURE 2 Total sperm motility at each time: percentage variations respect to T-1 (Time: P<.001; LACTX: P=.001). Group 1: patients treated with l-acetyl-carnitine (LAC), alone or combined. Group 2: patients treated with l-carnitine (LC) or placebo. Balercia. Carnitine therapy in asthenozoospermia. Fertil Steril 2005. Fertility and Sterility 2005 84, 662-671DOI: (10.1016/j.fertnstert.2005.03.064) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions
FIGURE 3 Forward sperm motility at each time: percentage variation respect to T-1 (Time: P<.001; LACTX: P=.001). Group 1: patients treated with l-acetyl-carnitine (LAC), alone or combined. Group 2: patients treated with l-carnitine (LC) or placebo. Balercia. Carnitine therapy in asthenozoospermia. Fertil Steril 2005. Fertility and Sterility 2005 84, 662-671DOI: (10.1016/j.fertnstert.2005.03.064) Copyright © 2005 American Society for Reproductive Medicine Terms and Conditions